Table 1.
Summary of the baseline (week 0) characteristics of the patients enrolled
| Variable | CinnaPoietin® (n = 78) | Eprex® (n = 78) |
|---|---|---|
| Age, years | 55.02±11.38 | 50.01±12.72 |
| Male, n (%) | 45 (57.69) | 45 (57.69) |
| BMI, kg/m2 | 25.5±5.99 | 25.09±4.66 |
| Hgb, g/dL | 10.41±0.89 | 10.64±0.82 |
| Hct, % | 32.37±3.91 | 33.12±3.24 |
| Ferritin, ng/mL | 674.42±410.88 | 626.15±320.47 |
| TSAT, % | 37.38±23.95 | 38.15±20.43 |
| CRP | 10.03±15.09 | 9.88±11.26 |
| History of high blood pressure, n (%) | 34 (43.59) | 14 (17.95) |
| History of diabetes type 1, n (%) | 7 (8.97) | 1 (1.28) |
| History of diabetes type 2, n (%) | 16 (20.51) | 4 (5.13) |
| History of Glomerulopathy, n (%) | 5 (6.41) | 2 (2.56) |
| Medication, n (%) | ||
| Calcium channel blockers | 10 (18.18) | 2 (5.71) |
| Statins | 6 (10.91) | 3 (8.57) |
| ACE/ARBs* | 16 (29.09) | 0 (0.00) |
| Beta blocker | 20 (36.36) | 1 (2.86) |
| Iron sucrose IV | 3 (5.45) | 29 (82.86) |
*
Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers.
Values are presented as mean ± SD unless stated otherwise.